trending Market Intelligence /marketintelligence/en/news-insights/trending/4cP1ex8O3ib6RXxxMCm2CQ2 content esgSubNav
In This List

Regulus Therapeutics receives Nasdaq noncompliance notice

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Regulus Therapeutics receives Nasdaq noncompliance notice

Regulus Therapeutics Inc. received a notice from the Nasdaq Stock Market for failing to meet the exchange's $1 minimum bid price listing requirement.

The company has 180 days to regain compliance.

The notice has no effect on the company's common stock listing at the time.